Latest & greatest articles for aripiprazole

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on aripiprazole or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on aripiprazole and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for aripiprazole

1. Comparison of the efficacy and safety of aripiprazole and brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials

Comparison of the efficacy and safety of aripiprazole and brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

2. Aripiprazole

Aripiprazole Top results for aripiprazole - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for aripiprazole The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

3. Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation). (PubMed)

Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation). People experiencing psychosis may become aggressive. Antipsychotics, such as aripiprazole in intramuscular form, can be used in such situations.To evaluate the effects of intramuscular aripiprazole in the treatment of psychosis-induced aggression or agitation (rapid tranquillisation).On 11 December 2014 and 11 April 2017, we searched the Cochrane Schizophrenia Group's Study-based Register (...) of Trials which is based on regular searches of CINAHL, BIOSIS, AMED, Embase, PubMed, MEDLINE, PsycINFO, and registries of clinical trials.All randomised controlled trials (RCTs) that randomised people with psychosis-induced aggression or agitation to receive either intramuscular aripiprazole or another intramuscular intervention.We independently inspected citations and, where possible, abstracts, ordered papers and re-inspected and quality assessed these. We included studies that met our selection

Full Text available with Trip Pro

2018 Cochrane

4. Risperidone versus aripiprazole as augmentation antipsychotics on the treatment of non-responsive Obsessive compulsive disorder

Risperidone versus aripiprazole as augmentation antipsychotics on the treatment of non-responsive Obsessive compulsive disorder Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

5. Digital aripiprazole (Abilify MyCite): a systematic review and meta-analysis of the evidence, and a review of its dissemination into the scientific literature, its press releases and its coverage in newspapers

Digital aripiprazole (Abilify MyCite): a systematic review and meta-analysis of the evidence, and a review of its dissemination into the scientific literature, its press releases and its coverage in newspapers Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files

2018 PROSPERO

6. Efficacy and safety of aripiprazole for schizophrenia: an overview of systematic reviews

Efficacy and safety of aripiprazole for schizophrenia: an overview of systematic reviews Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2017 PROSPERO

7. Long-acting aripiprazole (depot) versus placebo for schizophrenia [Cochrane protocol]

Long-acting aripiprazole (depot) versus placebo for schizophrenia [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2017 PROSPERO

8. Long-acting aripiprazole (depot) versus placebo for schizophrenia [Cochrane Protocol]

Long-acting aripiprazole (depot) versus placebo for schizophrenia [Cochrane Protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2017 PROSPERO

9. Aripiprazole versus ziprasidone for schizophrenia [Cochrane protocol]

Aripiprazole versus ziprasidone for schizophrenia [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures

2017 PROSPERO

10. Adjunctive aripiprazole in risperidone-induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial. (PubMed)

Adjunctive aripiprazole in risperidone-induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial. Hyperprolactinaemia is a troublesome side-effect of treatment with antipsychotics.This double-blind, placebo-controlled study aimed at examining the effect of adjunctive treatment with 10 mg aripiprazole on prolactin levels and sexual side-effects in patients with schizophrenia symptomatically maintained on risperidone.Thirty patients taking risperidone were enrolled (...) into the trial (CTRI/2012/11/003114). Aripiprazole was administered at a fixed daily dose of 10 mg/day for 8 weeks. Serum prolactin was measured at baseline and at 8 weeks. Hyperprolactinaemia-related problems, psychopathology and side-effects were evaluated every 2 weeks.Prolactin levels decreased by 58% in the aripiprazole group compared with an increase by 22% in the placebo group. Prolactin levels normalised in 46% of patients in the aripiprazole group (number needed to treat, NNT=2). Aripiprazole

Full Text available with Trip Pro

2016 BJPsych open Controlled trial quality: uncertain

11. Aripiprazole for autism spectrum disorders (ASD). (PubMed)

Aripiprazole for autism spectrum disorders (ASD). Autism spectrum disorders (ASD) include autistic disorder, Asperger's disorder and pervasive developmental disorder - not otherwise specified (PDD-NOS). Antipsychotics have been used as a medication intervention for irritability related to ASD. Aripiprazole, a third-generation, atypical antipsychotic, is a relatively new drug that has a unique mechanism of action different from that of other antipsychotics. This review updates a previous (...) Cochrane review on the safety and efficacy of aripiprazole for individuals with ASD, published in 2011 (Ching 2011).To assess the safety and efficacy of aripiprazole as medication treatment for individuals with ASD.In October 2015, we searched the Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE, Embase, the Cumulative Index to Nursing and Allied Health Literature (CINAHL) and seven other databases as well as two trial registers. We searched for records published in 1990 or later

Full Text available with Trip Pro

2016 Cochrane

12. Aripiprazole for Patients with Bipolar Disorder: A Review of the Clinical Effectiveness, Cost-effectiveness and Guidelines

Aripiprazole for Patients with Bipolar Disorder: A Review of the Clinical Effectiveness, Cost-effectiveness and Guidelines Aripiprazole for Patients with Bipolar Disorder: A Review of the Clinical Effectiveness, Cost-effectiveness and Guidelines | CADTH.ca Find the information you need Aripiprazole for Patients with Bipolar Disorder: A Review of the Clinical Effectiveness, Cost-effectiveness and Guidelines Aripiprazole for Patients with Bipolar Disorder: A Review of the Clinical Effectiveness (...) , Cost-effectiveness and Guidelines Published on: May 25, 2016 Project Number: RC0780-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical efficacy of aripiprazole alone or as part of combination therapy for the treatment of bipolar disorder? What is the cost-effectiveness of aripiprazole alone or as part of combination therapy for the treatment of bipolar disorder? What are the evidence-based guidelines regarding the use

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

13. The Treatment of Adult Bipolar Disorder with Aripiprazole: A Systematic Review. (PubMed)

The Treatment of Adult Bipolar Disorder with Aripiprazole: A Systematic Review. Bipolar disorder is characterized by exacerbations of opposite mood polarity, ranging from manic to major depressive episodes. In the current nosological system of the Diagnostic and Statistical Manual - 5(th) edition (DSM-5), it is conceptualized as a spectrum disorder consisting of bipolar disorder type I, bipolar disorder type II, cyclothymic disorder, and bipolar disorder not otherwise specified. Treatment (...) of all phases of this disorder is primarily with mood stabilizers, but many patients either show resistance to the conventional mood stabilizing medications or are intolerant to their side-effects. In this setting, second-generation antipsychotics have gained prominence as many bipolar subjects who are otherwise treatment refractory show response to these agents. Aripiprazole is a novel antipsychotic initially approved for the treatment of schizophrenia but soon found to be effective in bipolar

Full Text available with Trip Pro

2016 Curēus

14. Aripiprazole as an Adjunct to Anti-depressants for Major Depressive Disorder: Clinical Effectiveness, Cost-effectiveness, and Guidelines

Aripiprazole as an Adjunct to Anti-depressants for Major Depressive Disorder: Clinical Effectiveness, Cost-effectiveness, and Guidelines Aripiprazole as an Adjunct to Anti-depressants for Major Depressive Disorder: Clinical Effectiveness, Cost-effectiveness, and Guidelines | CADTH.ca Find the information you need Aripiprazole as an Adjunct to Anti-depressants for Major Depressive Disorder: Clinical Effectiveness, Cost-effectiveness, and Guidelines Aripiprazole as an Adjunct to Anti-depressants (...) for Major Depressive Disorder: Clinical Effectiveness, Cost-effectiveness, and Guidelines Published on: May 4, 2016 Project Number: RA0846-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question 1. What is the clinical efficacy of aripiprazole as an adjunct to antidepressants for the treatment of patients with major depressive disorder who have had an inadequate response to prior antidepressant treatments? 2. What is the cost-effectiveness of aripiprazole

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

15. Pharmacological interventions: Is long-acting injectable aripiprazole useful for the treatment of acute exacerbation of schizophrenia?

Pharmacological interventions: Is long-acting injectable aripiprazole useful for the treatment of acute exacerbation of schizophrenia? Is long-acting injectable aripiprazole useful for the treatment of acute exacerbation of schizophrenia? | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Is long-acting injectable aripiprazole useful for the treatment of acute exacerbation of schizophrenia? Article Text Further commentaries Electronic pages

2016 Evidence-Based Mental Health

16. Efficacy and safety of adjunctive aripiprazole in patients with schizophrenia-spectrum disorder: a meta-analysis of randomized controlled trials

Efficacy and safety of adjunctive aripiprazole in patients with schizophrenia-spectrum disorder: a meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2016 PROSPERO

17. The efficacy and tolerability of aripiprazole for tic disorders in children and adolescents: a systematic review and meta-analysis

The efficacy and tolerability of aripiprazole for tic disorders in children and adolescents: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2016 PROSPERO

18. Meta-analysis of adjunctive aripiprazole for antipsychotic-related hyperprolactinemia in patients with first episode schizophrenia

Meta-analysis of adjunctive aripiprazole for antipsychotic-related hyperprolactinemia in patients with first episode schizophrenia Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2016 PROSPERO

19. Aripiprazole versus sulpiride for people with schizophrenia and schizophrenia-like psychoses [Cochrane Protocol]

Aripiprazole versus sulpiride for people with schizophrenia and schizophrenia-like psychoses [Cochrane Protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2016 PROSPERO

20. Aripiprazole versus perphenazine for people with schizophrenia and schizophrenia-like psychoses [Cochrane Protocol]

Aripiprazole versus perphenazine for people with schizophrenia and schizophrenia-like psychoses [Cochrane Protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2016 PROSPERO